Carbidopa And Levodopa Tablet, Orally Disintegrating
NDC Package 16571-159-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Carbidopa And Levodopa tablets is carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.Carbidopa allows patients treated for Parkinson’s disease to use much lower doses of levodopa. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Rising Pharma Holdings, Inc., this product is identified by NDC 16571-159 and is authorized under FDA application ANDA078893.

Identification & Billing

NDC Package Code
16571-159-01
Package Description
100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC
Product Code
16571-159
11-Digit Billing Format
16571015901
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk
  • RxCUI: 476399 - carbidopa 25 MG / levodopa 100 MG Disintegrating Oral Tablet
  • RxCUI: 476399 - Carbidopa 25 MG / L-DOPA 100 MG Disintegrating Oral Tablet
  • RxCUI: 476515 - carbidopa 25 MG / levodopa 250 MG Disintegrating Oral Tablet
  • RxCUI: 476515 - Carbidopa 25 MG / L-DOPA 250 MG Disintegrating Oral Tablet
  • RxCUI: 483090 - carbidopa 10 MG / levodopa 100 MG Disintegrating Oral Tablet

Clinical Specifications

Proprietary Name
Carbidopa And Levodopa
Non-Proprietary Name
Carbidopa And Levodopa
Substance Name
Carbidopa; Levodopa
Dosage Form
Tablet, Orally Disintegrating - A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.Carbidopa allows patients treated for Parkinson’s disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa orally disintegrating tablets. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa.Carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa.

Regulatory & Marketing

Labeler Name
Rising Pharma Holdings, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA078893
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-08-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16571-159-01 identifies a specific commercial package of 100 tablet, orally disintegrating in 1 bottle, plastic of Carbidopa And Levodopa, a human prescription drug labeled by Rising Pharma Holdings, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 100 billable units per package. This tablet, orally disintegrating is formulated for oral use and contains carbidopa; levodopa as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Rising Pharma Holdings, Inc. on January 08, 2025. The current certification is valid through December 31, 2027.

How is this Rising Pharma Holdings, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16571015901. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16571-159-01
11-Digit CMS (5-4-2)
16571-0159-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.